Member Info for CityTTrader

Love this article. Needs to be sent to all the media outlets we can send it to.

Looks as though the phone call to RM upset someone.

Some idiots seem to have appeared here thinking thy can drop the SP by posting rumours and stupidity. Its not working. :-)

SNG was doing well until the vaccines were announced. Strangely the market didn't spot them coming until the very day they were announced! So began the cut of a thousand knives and a winter of discontent with the SP dropping below 90p. Yet the vaccines will take time delivering and people are still going to die. Finally the market began to recognise this and the SP has risen.

Then began the news that vaccine supply is slow, there's a shortage of vials and allergic reactions to the vaccine are greater than planned. Now we have varients such as the South Africa strain which is possibly resistant to CV19. Its not looking quite so good for the vaccine.

SNG001 now out there in what we hope are final trials and being watched around the world except for the UK. Uses a natural protein so should be very safe with no allergic reactions. Saves lives and shorten hospital stays looks to b the best therapeutic out there by a country mile.

The market will one day realise that saving lives is as important as vaccines and we shall be rewarded.

GLA.

Have to agree Tikvah have just caught up with their % holdings. Dilution not share sale after all. Good to know.

polar might be looking to buy another 2.5m. If so there might be a new price negotiated?

CR
A company will engage a broker to buy x amount at a price. The broker hopes to buy them cheaper than the agreed price an make a profit but sometimes the price rises beyond their control and they have to buy to keep the client happy even though it costs them. The last thing they want is to fail because the client will simply go to a different broker and use them for other future trades
There are many ways of keeping the SP down by using the spread, create sudden dops and use the famous 1 trade telling others to keep the price down etc.

I'm hoping they keep buying.

They've not understood the product and how it helps COPD.

I'm sticking with a £3bn valuation or £15 a share.

https://lemminginvestors.blogspot.com/2021/01/my-2021-picks.html

Synairgen (SNG) 140p is a potential lotto ticket. We have already seen the excitement this company can offer on the back of a good RNS. I was foolish enough to cash in on what I thought was a healthy 195% gain in early trading...I left 300% on the table. The share price had since retraced to levels still under the 175p when it raised £80m, now at 140p Synergain is bubbling again.

The big hope here is for the therapeutics SNG001 provides supplies with an answer to Covid-19 which is on the FDA fast-track for possible review for FDA approval. PHASE 2 has already demonstrated significant benefits, good enough to be published in the world-renown Lancet. Synairgen has teamed up with Parexel to enable such a large amount of research to be conducted and ''enable rapid approvals worldwide.''
CEO Marsden says if all goes to plan ''we would have finished a phase II and III programme all in one year, which is very unusual.''
Fireworks are expected if the FDA gives the go-ahead having implored Synairgen to slightly modify and reduce the phase 3 parameters.

Also worthy of note has a fibrosis drug licensed to Pharmaxis, which should be licensed out to 3rd parties for which Synairgen gets a 17% of upfront milestone and royalties.

Key Event

If SNG001 gains FDA approval I seriously doubt Synairgen will survive as an independent entity, it will almost certainly be gobbled up by a larger pharmaceutical company. This is not just my opinion, it is the opinion of city sources. If I am correct, then Synairgen will command multi-bag status from here, possible ahead of Open Orphan. Without checking, I think Numis has a valuation of £9.90p anyway.

I can see a $3bn company here within months. So for me it £15 before June.

Professor Nick Lemoine, Medical Director of the NIHR Clinical Research Network said:
“Results from early phase research into Synairgen’s respiratory treatment, SNG001, show this drug’s potential as an effective therapeutic option for Covid-19. As an urgent public health study, the phase 3 trial will now be prioritised for fast track set-up and delivery across the NHS - on a much larger scale. This will give many more UK patients the opportunity to take part and potentially benefit from this exciting new treatment, as we move into the second wave.

“NIHR-supported research has already given the world the first proven treatments against this new disease. We are pleased to further support the incredible innovation emanating from the UK by delivering this large-scale trial of a Covid-19 drug developed by Synairgen - a UK biotech firm.

If this turns into £10bn company then its £50 a share.

I would just like to thank the shorters for allowing me to buy, buy and buy these shares so cheaply. I guess the rising SP means that they will soon be losing money but such is the market. You shorters need to understand that a share like this is about to save millions. There are not too many shares and the price is about to rise steeply.

So we shall be bought out for £400m? Not going to happen. I'm looking for £3-4BN. A lot more than double.

TR1 must be due!

https://www.dailymail.co.uk/news/article-9074747/Russian-scientist-falls-death-window-stabbed-latest-mysterious-death.html

Despite a huge paper loss I spent the last 2 weeks buying. To me it was obvious that we would eventually bounce back to 250p, which i where we are heading now. Then we are off to the moon and back. Enjoy the ride all. GLA.

Just remember peees the placing at 175p was oversubscribed. Plenty more room for the SP to rise IMHO. GLA.